Clinical Trial

Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-10-13; most recent amendment 2025-02-12.
Status change: Recruiting → Active, Not Recruiting 2024-10-29
Trial Details
NCT Number NCT05580991
Lead Sponsor Canwell Biotech Limited
Conditions Solid Tumor
Enrollment 27 participants
Start Date 2022-09-09
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-13